The ADAGIO study was a 18-month, placebo – controlled, double – blind, multi center study with a delayed start design, in patients with early, previously untreated Parkinson’s disease . Subsequent analyzes were performed on placebo patients , including a subgroup analysis of patients with high and low baseline total UPDRS scores performed. Overall, the rate of progression of the subjects in the placebo group was slower than expected , recruited despite the fact that the subjects were in an earlier stage of disease progression than other studies, and the belief that dopaminergic cell loss was thinking ahead faster in the earlier stages of the disease..
The placebo analyzes demonstrated that the natural progression of clinical symptoms in PD may be slower expect in the early stages of disease development than from previous findings. These results could impact results for the entire interpretation of the ADAGIO. In particular, the clinical significance of 1, 7 UPDRS units between the AZILEC 1 mg / day early and delayed – start groups during the 9 months period is, on average, seen a 40 % reduction compared to the baseline in the early group when compared the delayed group.Wide neck Onyx HD 500 gets HDE FDA approval to treatment of cerebral aneurysms.
On ev3 Inc. – ev3 is a global organization concentrated to medical device on the catheter – based technology for endovascular treatment of vascular disease and disorders. For more information , please visit.